0/1-Hour Algorithm Safe and Effective for Rapid Chest Pain Assessment in the ED: DROP-Asian ACS Trial
Key Takeaways: The 0/1-hour hs-cTn algorithm is safe, non-inferior to usual care, and significantly increases ED discharge rates while reducing short-term cardiac... Read more.
Routine Orbital Atherectomy Does Not Improve Outcomes vs Balloon Angioplasty for Severely Calcified Coronary Lesions: ECLIPSE Trial
Key Takeaways: Orbital atherectomy as a routine lesion preparation strategy prior to stenting did not reduce clinical events or improve stent expansion compared... Read more.
AI-Quantitative CT Coronary Plaque Features Indicate Higher Relative CV Risk in Women: CONFIRM2 Registry
Key Takeaways: AI-based quantitative coronary plaque assessments significantly improve risk prediction for cardiovascular events in women compared to traditional... Read more.
First-in-Human Gene Therapy (TN-201) Shows Promising Results in MYBPC3-Associated HCM
Key Takeaways: TN-201, a first-in-class gene therapy, was well tolerated and showed stable cardiac gene expression, improved biomarkers, and symptom relief in patients... Read more.
Artificial Intelligence Enables Novices to Perform Diagnostic-Quality Echocardiography: HeartFocus Study
Key Takeaways: AI-guided echocardiography enables novice users to obtain diagnostic-quality cardiac images comparable to expert sonographers, achieving perfect diagnostic-quality... Read more.
Survival After Sudden Cardiac Arrest Improves in Young Athletes, but Racial Disparities Persist
Key Takeaways: Survival from sudden cardiac arrest among young competitive athletes increased significantly from 38% to 66% over the last decade, driven by enhanced... Read more.
Geographic Variations in Racial Disparities for Peripheral Artery Disease Treatment in the U.S.
Key Takeaways: Black patients with peripheral artery disease (PAD) had significantly higher major amputation rates than White patients across all U.S. states (3.0%... Read more.
Zerlasiran Was Well Tolerated and Reduced Time-averaged Lp(a) Concentration: The ALPACAR Trial
Key Takeaways: Zerlasiran, a short interfering RNA (siRNA) targeting lipoprotein(a) (Lp(a)), was well tolerated and led to significant reductions in Lp(a) serum... Read more.
AMULET IDE Trial 5 years Showed Long-term Safety and Efficacy of AMPLATZER Amulet and Watchman Device in LAAO
Key Takeaways: The AMULET IDE trial compared the AMPLATZER Amulet occluder with the Watchman 2.5 device in patients with nonvalvular atrial fibrillation (NVAF) at... Read more.
Oral Muvalaplin Lowered Lipoprotein(a): The KRAKEN Trial
Key Takeaways: KRAKEN was an international, multicenter, placebo controlled, phase 2 trial that tested the effects of muvalaplin at different doses—10 mg, 60 mg... Read more.